REFERENCES
- Brogden RN, Ward A. Ceftriaxone: a reappraisal of its antibacterial activity and pharmacokinetic properties, and an update on its therapeutic use with particular reference to once-daily administration. Drugs 1988; 35: 604–605.
- Stratton CW, Anthony LB, Johnston PE. A review of ceftriaxone: a long acting cephalosporin. Am J Med Sci 1988; 296: 221–222.
- Barson WJ, Miller MA, Brady MT, Powell DA. Prospective comparative trial of ceftriaxone versus convention-al therapy of bacterial meningitis in children. Ped Infect Dis 1985; 4: 362–368.
- Lin T-Y, Chrange DF, Nelson JD, McCracken GH. Seven days of ceftriaxone therapy is as effective as ten days treatment for bacterial meningitis. J Am Med Assoc 1985; 253: 3559–3563.
- Girgis NI, Kilpatrick ME, Farid, Z, Mikhail IA, Bishay E. Ceftriaxone versus chloramphenicol in treatment of enteric fever. Drugs Under Exp Clin Res 1990; 16: 607–609.
- Lasserre R, Sangalang RP, Santiago P. Three-day treat-ment of typhoid fever with two different doses of ceftriaxone compared to 14-day therapy with chloramphenicol. J Antimicrob Chemother 1991; 28: 765–772.
- Woodfield JC, Van Rij AM, Pettigrew RA, van der Linden AJ, Solomon C, Bolt D. A comparison of the efficacy of ceftriaxone and cefotaxime in abdominal surgery. Am J Surg 2003; 185 (1): 45–49.
- Meredith P.A. Generic drugs: therapeutic equivalence. Drug Safety 1996; 15 (4): 233–242.
- Shaw NJ, Lyall EGH. Hazards of Glass Ampoules. Br Med J 1985; 291:1390.
- Cant AJ, Lenny W, Kirkham N. Plastic material from a syringe causing fatal bowel necrosis in a neonate. Br Med J 1988; 296: 968–969.
- Falchuk KH, Peterson L, McNeil BJ. Microparticulate induced phlebitis. N Engl J Med 1985; 312: 78–82.
- Kirkpatrick CJ. Particulate matter in intravenous fluids. The importance for medicine. Krankenhauspharmazie 1988; 9: 487–490.
- Walpot H, Francke RP, Burchard WG, Agtemkamp Chr, Mueller FG. Particulate contamination of intravenous solutions and drug additives during long-term intensive care Part 1. Back scattering electron images under scanning electron microscope - SEM/EDX. Anaesthetist 1989; 38: 544–548.
- Kirkpatrick CJ. Aspects of the pathogenesis of multiple organ failure. ECG Int 1990; 2: 177–182.
- SOP (2002). Standard operating procedures 0600 SPQR.001 C AV Roche Pharmaceuticals. Rocephin Substance sterile. Ceftriaxone disodium salt sterile.
- United States Pharmacopoeial Convention (USPC), (2002). United States Pharmacopoeia and the National formu-lary (U5P25, NF20). Published by The Stationery Office.
- European Directorate for the Quality of Medicines (EDQM), (2003). European Pharmacopoeia 4th Edition ISBN 9287 145873. Published by The Stationery Office (2003).
- Munsell Book of Color 1996. GretagMacbeth, 617 Little Britain Road, New Windsor, New York 12553-6148.
- 50P0600 SQVU.001-XRF ‘Use and reporting of the heavy metal test by X-ray fluorescence spectroscopy’.
- SOP 0600 SQVU.002-XRF ‘Basic methods for X-ray fluorescence spectroscopy’.
- FDA. 1987. Guideline on validation of the limulus ame-bocyte lysate test as an end product endotoxin test for human and animal parenteral drugs, biological products and medical devices. http://www.fda.gov/cder/guidance/index.htm
- Davidson AG, McCallum A. A survey of the stability of omeprazole products from 13 countries. Drug Develop Ind Pharm 1996 22: 1173-1185.